2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 63, n° 3
pages 448-456 (septembre 2010)
Doi : 10.1016/j.jaad.2009.09.040
accepted : 23 September 2009
Original Articles

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Alan Menter, MD a, , Kenneth B. Gordon, MD b, Craig L. Leonardi, MD c, Yihua Gu, MS d, Orin M. Goldblum, MD d
a Baylor Psoriasis Research Institute, Dallas, Texas 
b Northwestern University, Evanston, Illinois 
c Central Dermatology Inc, St Louis, Missouri 
d Abbott Laboratories, Abbott Park, Illinois 

Correspondence to: Alan Menter, MD, Baylor Psoriasis Research Institute, Baylor University Medical Center, 3900 Junius St, Suite 145, Dallas, TX 75246.

The phase III r andomized controlled ev aluation of adalimumab e very other week dosing in moderate to severe psoriasis trial (REVEAL) demonstrated adalimumab induced significant improvements and was well tolerated for patients with moderate to severe psoriasis.


We sought to determine the efficacy and safety of adalimumab for various subgroups of patients in REVEAL with moderate to severe psoriasis and to determine whether these profiles were consistent with the overall results.


Patients (N = 1212) with moderate to severe psoriasis were randomized to adalimumab or placebo during the first 16 weeks of the trial. The primary efficacy endpoint was percentage of patients achieving at least 75% improvement in the Psoriasis Area and Severity Index (PASI) score at week 16. Post hoc subgroup analyses were conducted to determine relationships between adalimumab efficacy and/or safety and age group, sex, race, baseline weight intervals, baseline body mass index, disease duration, baseline severity, prior treatments, and comorbidities.


Consistent 75% or greater improvement in the PASI score responses were observed across all patient subgroups, with moderately reduced responses noted for patients in the greater weight and body mass index categories. A multivariate analysis identified treatment received, weight, and age as the most influential factors for mean percentage change in PASI score at week 16. No significant differences in the risk of serious adverse events in adalimumab- versus placebo-treated patients were observed across weight categories or for patients with baseline comorbidities.


These subanalyses are limited by their relatively short, 16-week duration.


Treatment of moderate to severe psoriasis with adalimumab led to consistent 75% or greater improvement in PASI score response rates across the majority of patient subgroups, with no significant differences in serious adverse events.

The full text of this article is available in PDF format.

Key words : age, body mass index, body weight, disease duration, health-related quality of life, race, symptom severity, tumor necrosis factor antagonist

Abbreviations used : AE, BMI, BSA, PASI, PASI 75, PGA, PsA, REVEAL

 Funding for manuscript development was provided by Abbott Laboratories, with editorial support provided by Michael A. Nissen, ELS, of Abbott Laboratories, and Arbor Communications Inc.
 Disclosure: Dr Menter is a consultant and member of the advisory boards and speakers bureaus of Abbott Laboratories, Amgen, Astellas, Centocor, Genentech, and Wyeth; he is a consultant and investigator for Eli Lilly; and he has received investigator funding from Abbott Laboratories, Amgen, Astellas, Centocor, Genentech, and Novo Nordisk. Dr Gordon has received investigator funding and consulting fees from and serves as a member of the advisory boards of Abbott Laboratories, Amgen, Centocor, Galderma, and Novo Nordisk. Dr Leonardi is a consultant for Abbott Laboratories, Amgen, Centocor, and Genentech and is an investigator for Abbott Laboratories, Allergan, Altana, Amgen, Astellas, Biogen, Bristol-Myers Squibb, Centocor, CombinatoRx, Fujisawa, Galderma, Genentech, RTL, Schering-Plough, Serono, Vitae, and 3M Pharmaceuticals; he also received an educational grant from Amgen and Genentech, and is part of the speakers bureaus for Abbott Laboratories, Amgen, Centocor, Genentech, and Warner Chilcott. Ms Gu and Dr Goldblum are employees of Abbott Laboratories.
 Reprints not available from the authors.

© 2009  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline